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Experimental models closely representing in vivo conditions allow investigating mecha-
nisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural 
mesothelioma (MPM) samples and to obtain proof of principle that primary culture 
chemoresistant models, mimicking tumor progression observed in patients, can be 
obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary 
mesothelioma cultures were established from 235 samples between 2007 and 2014. Of 
two MPM patients, primary cultures obtained at different time points: at initial diagnosis, 
after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply 
investigated. Cells and corresponding tumor tissue were characterized by mesothelial 
protein and gene expression analysis. In addition, primary cultures from chemo naive 
patients were exposed to increasing doses of cisplatin/pemetrexed during three months 
and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of 
senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures 
was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM sam-
ples was significantly associated with poor overall survival in the TCGA MPM cohort. Our 
results illustrate that the establishment of a large live-cell MPM biobank contributes to a 
better understanding of therapy resistance observed in vivo, which eventually may lead 
to a more logical approach for developing new treatment strategies.
Keywords: mesothelioma, primary culture, tumor progression, chemoresistance, genetic profiling, mutations, 
copy number, cisplatin and pemetrexed
inTrODUcTiOn
Malignant pleural mesothelioma (MPM) is an asbestos-related cancer arising from mesothelial cells 
of the pleura. The prognosis of MPM patients is poor [median survival of 12 months (1)] likely 
because in most cases diagnosis is made in advanced disease stages. A recent large-scale study based 
on pathological samples has comprehensively characterized most genetic alterations and distinct 
molecular profiles in MPM (2). However, there is still the need of experimental models to define 
cancer driver activity of a given genetic alteration, like it has been done with the Nf2-(3–5) and 
Bap1-deficient mice (6, 7). Experimental models may closely resemble in vivo conditions and allow 
for the testing of novel therapeutic approaches to understand their mechanism of action.
Moreover, experimental models allow for the investigation of resistance mechanisms. Patient-
derived xenografts in humanized NSG mice (https://www.jax.org/news-and-insights/jax-blog/2015/
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april/the-next-big-thing-in-cancer-modeling-patient-derived-
xenografts-in-humaniz) would represent the best overall model 
but currently are difficult to implement for routine purposes. In 
contrast, cell lines are an easy accessible disease model (8) that is 
still accepted for certain investigations, such as molecular mecha-
nism of drug action. Primary mesothelioma cultures were shown 
as valid model for mechanisms of resistance to pemetrexed, which, 
in combination with platinum compounds, is a component of 
current MPM standard neoadjuvant treatment (9). According to 
Cellosaurus (http://web.expasy.org/cgi-bin/cellosaurus/search) 
there are 402 human mesothelioma cell lines available. Of these 
cell models, only 11 have a well-profiled genotype (https://por-
tals.broadinstitute.org/ccle/home) and for 45, fingerprinting for 
identification is available. In addition, long-term passaging leads 
to genetic drift caused by genomic instability. A recent study (10) 
demonstrated an upregulation of glycolytic and oxidative phos-
phorylation in commercial lines compared to primary cultures. 
In addition, primary cells maintain expression of podoplanin, 
which is lost in commercial lines and they show activation of the 
type I interferon signaling pathway (10).
In this study, we tested the hypothesis whether molecular 
profiling of primary mesothelioma cell culture obtained from 
patients with MPM are helpful to understand the mechanisms 
of acquired resistance to cisplatin/pemetrexed treatment in vivo.
MaTerials anD MeThODs
Tumor
Tissue samples were obtained from patients treated for MPM 
at the Department of Medical Oncology and Department of 
Thoracic Surgery between January 2007 and December 2014. 
The study has been approved by the Zurich Cantonal Ethics 
Committee (reference numbers StV 24-2005 and 29-2009). 
Written informed consent was obtained from all patients. Tumor 
samples obtained from diagnostic biopsies prior to neoadjuvant 
chemotherapy and the corresponding resection specimens were 
processed immediately for total RNA extraction using Qiagen 
RNAeasy kit (Qiagen, Hilden, Germany). In addition, another 
part of the tumor samples was embedded in OCT and immedi-
ately frozen at −80°C. The remaining tumor samples were fixed in 
4% buffered formaldehyde for paraffin embedding.
cell culture and senescence-associated-
β-gal activity
Primary mesothelioma cell cultures were generated as previously 
described (11). In order to establish a model for chemoresistance, 
two primary cultures from chemotherapy-naive epithelioid MPM 
specimens were continually exposed to low doses of cisplatin and 
pemetrexed according to a previously published method of cispl-
atin-resistance in ovarian cancer cell lines (12). These two cultures 
originated from two MPM patients. The first primary culture was 
taken from a biopsy of a male 69-year-old patient (P95), who 
had an epithelioid MPM (Figures S1 and S2 in Supplementary 
Material) and was enrolled into the SAKK17/04 study (13). The 
patient, therefore, underwent extrapleural pneumonectomy after 
neoadjuvant chemotherapy but relapsed 15 months later. He died 
27  months after the initial diagnosis. The second culture was 
established from a female, 50-year-old patient (P236) with papil-
lary epithelioid tumor morphology (Figure S1 in Supplementary 
Material). The patient underwent partial pleurectomy (Figure S2 
in Supplementary Material) but relapsed 19 months later and was 
operated again, followed by chemotherapy. Unfortunately, the 
patient died 3 years after the first surgery. In the two chemo-naive 
primary cultures, cells were treated with cisplatin at the initial 
dose of 3 and 1 nM pemetrexed. The treatment was conducted in 
three cycles, including 4 days of treatment and 3 days of recovery 
time. The concentration was doubled and the procedure was 
repeated until the concentration of cisplatin and pemetrexed 
reached 48 and 16 nM, respectively. Chemoresistance induction 
was evaluated based on the cytotoxicity to a subsequent exposure 
to cisplatin and pemetrexed. Doubling time was estimated as 
previously described (14). Primary cells were authenticated by 
DNA fingerprinting of short tandem repeat loci (Microsynth, 
Switzerland). Senescence-associated-β-gal activity was deter-
mined as previously described (15).
relative gene expression
To extract RNA, Qiagen RNeasy kit was used. cDNA was deter-
mined as previously described (15). Selected gene expression 
[primers are listed in Table S1 in Supplementary Material and 
(15–17) analysis using MIQE compliant protocols (18)] was 
conducted as previously described.
Western Blotting
Whole cellular protein extracts were prepared in 95°C Laemmli 
sample buffer and mechanically sheared by pressing few times 
through syringes (26 G). Protein concentration was determined 
using a Pierce™ 660  nm Protein Assay (Thermo Scientific). A 
total of 5  µg protein per extract was separated on denaturing 
10–20% gradient SDS-PAGE gels. Proteins were transferred on 
PVDF transfer membranes (0.45 µm, Perkin Elmer). Membranes 
were probed with the following primary antibodies: anti-
calretinin (Sigma, HPA007306), mouse anti-actin (#69100) from 
MP Biomedicals, N-Cadherin (BD Biosciences, 610920), YAP 
(Cell Signaling 4912), Mesothelin (Rockland Inc. 200-301-A88), 
GATA4 (C-20) (Santa Cruz sc-1237), p62 (Progen GP62-C), 
LC3B (Cell Signaling 2775S), p53 (DO-1) (Santa Cruz sc-126), 
Thy1 (H-110) (Santa Cruz sc-9163), and γ-H2AX (Millipore 
05-636). Membranes were then incubated with the secondary 
antibody rabbit anti-mouse IgG-HRP (A-5420) from Antell, and 
goat anti-rabbit IgG-HRP (#7074) from Cell Signaling. The signals 
were detected by enhanced chemiluminescence (ECL™ Western 
Blotting Reagents, GE Healthcare) and detected on photosensi-
tive film (Super RX Fuji x-Ray Film, Fujifilm). Proteins were 
quantitated with densitometry using Image J software (Version 
1.42q, USA).
immunofluorescence
Primary cells were grown on 12-mm glass coverslips in 24-well 
plates. Cells were fixed for 10 min with 4% paraformaldehyde 
and permeabilized with 0.05% saponin for 5  min. The cells 
were then incubated over night at 4°C with Calretinin (N-term) 
(Sigma HPA007306), Podoplanin (D2-40) (Dako M3619), YAP1 
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(Cell Signaling 4912), Ki67 (Abcam ab8191), Phalloidin 488 
(molecular probes A12379), Thy1 (H-110) (Santa Cruz sc-9163), 
and N-Cadherin from Dako (M3613) diluted in PBS containing 
1% bovine serum albumin. Secondary antibodies, Alexa Fluor 
488-conjugated goat anti-rabbit IgG (Life Technologies A11034) 
and Alexa Fluor 555-conjugated goat anti-mouse IgG (Life 
Technologies A21424) antibody was added for 1 h at RT. Nuclear 
DNA was stained using DAPI. Coverslips were mounted using 
Prolong Gold antifade reagent (Life Technologies). Images were 
acquired using an Olympus BX61 microscope (Schwerzenbach, 
Switzerland) equipped with an F-view camera for conventional 
fluorescence imaging. The image capture was controlled with 
the AnalySISPro software (Soft Imaging System, Münster, 
Germany).
surface Phenotyping
Cells resuspended in ice-cold PBS/2mM EDTA were incubated 
with antibodies against Thy1 (H-110) (Santa Cruz sc-9163) at 4°C 
for 30 min in the dark. Secondary antibody (PE-labeled, Dianova) 
was incubated at 4°C for 30 min in the dark. After washing with 
PBS cells were resuspended in ice-cold PBS/2mM EDTA and 
fluorescence was measured on an Attune flow cytometer (Applied 
Biosystems) and analyzed with the Attune cytometric software 
v1.2.5 (Applied Biosystems).
genetic alterations
For DNA isolation from formalin-fixed, paraffin-embedded 
(FFPE) tissue, two punches of 0.6 mm were taken from the tumor 
of each FFPE Block. DNA was extracted using the Maxwell 16 
FFPE Tissue LEV DNA Purification Kit (Promega) according 
to the manufacturer’s protocol. Isolated DNA was diluted in 
nuclease-free water and the concentration was measured by fluo-
rometric quantitation using the Qubit 2.0 fluorometer (Thermo 
Fisher Scientific).
For targeted amplicon-based sequencing, we developed a 
custom-designed Ion AmpliSeq MPM Panel (Thermo Fisher 
Scientific), covering the coding regions of 30 genes that were 
reported to be commonly mutated in MPM. 10  ng of either 
FFPE tumor or primary cell DNA were used as an input for 
library preparation, following the Ion AmpliSeq DNA Library 
Preparation user guide (Thermo Fisher Scientific). Template 
preparation and sequencing was performed according to the 
manufacturer’s protocol (Ion PI Hi-Q OT2 200 Kit User Guide 
and Ion PI Hi-Q Sequencing 200 Kit, Thermo Fisher Scientific). 
Alignment, variant calling, and filtering of the resulting data were 
performed with Ion Reporter 5.0 (Thermo Fisher Scientific). The 
filtering chain included removal of all synonymous mutations, 
variants that are found in the UCSC Common SNPs database, 
variants with an allele ratio below 10% or a read count below 
50. Additionally, all mutations were visually inspected, using the 
Integrative Genomics Viewer Software (Broad Institute).
For array-based genome wide copy number analysis, 
OncoScan FFPE microarrays (Affymetrix) were conducted at 
IMGM Laboratories GmbH (Martinsried, Germany). An input 
amount of 79.2 ng DNA was used for the assay. Molecular inver-
sion probe processing was carried out according to the OncoScan 
FFPE Assay Kit Protocol (Affymetrix). For data analysis, the 
AGCC Viewer v4.2.1567 and the OncoScan Console v1.3.0.39 
were used (Affymetrix). Copy number variation (CNV) and loss 
of heterozygosity (LOH) analysis was performed using the Nexus 
Express for OncoScan v3.1 software. CNVs were visualized using 
Circos19. Oncoscan have been deposited in GEO (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109305).
statistics
Data are expressed as mean ±  SD. Statistical analysis was per-
formed using Mann–Whitney U tests using StatView 5.0.1 (SAS 
institute) and t-test using GraphPad. Differences were considered 
statistically significant at p < 0.05.
resUlTs
Primary cultures reflect Tumor 
characteristics
Between 2007 and 2014, 235 surgical samples were obtained and 
processed, as described in Figure 1A. After preservation of tumor 
material for histopathological evaluation, remaining parts of the 
tumor were processed in order to extract RNA. Derived cDNA 
was then used for quality control assays, i.e., for calculation of the 
MPM score (15), allowing to determine that 82% of the samples 
contained at least 50% tumor cells. In case of large representative 
tumor tissue, additional parts of the fresh sample were used to 
establish primary cultures, either in the presence of serum (11) or 
in the absence of serum (17), for enzymatic analysis (15) or in situ 
hybridization (17). Successful primary cultures from “bona fide” 
tumor samples, defined as sufficiently growing cells for collecting 
RNA and total protein lysates, and preparing frozen stocks, was 
achieved in 68% of initial samples (159/235).
Primary cultures from two patients (P236 and P95) for 
whom samples were available at different stages of the disease 
(for nomenclature defining the different samples from these 
patients see Figure S2 in Supplementary Material) and where 
we had observed maintenance of epithelioid histology in one 
(P236) and epithelial to mesenchymal transition (EMT) in the 
second (P95), were selected for this proof of principle study. It 
is worth noting that EMT was evaluated on surgical specimens 
excluding any diagnostic bias introduced by single biopsy 
analysis. For these two patients, established primary cultures 
from different time points were compared with matching initial 
tumor samples by short tandem repeat analysis (Table S2 in 
Supplementary Material), Oncoscan CNV testing, and amplicon 
panel sequencing (Figure 1B). While few genetic alterations were 
present in P236, consistent with current knowledge on papillary 
mesothelioma (19), P95 was characterized by a widespread LOH 
including NF2, BAP1, and TP53 tumor suppressor genes, as 
well an additional truncating mutation in NF2 (c.553G >  T/p.
Glu185Ter, no Cosmic annotation) and a point mutation in TP53 
(c.839G > C/p.p.Arg280Thr, cosm254987).
N-cadherin, mesothelin, and calretinin MPM biomarker 
mRNA and protein expression was determined (Figure  1C) 
and decreasing calretinin expression reflected the evolution 
of the tumor. A high level of YAP expression was observed in 
all cultures. Culture heterogeneity was evidenced in one of the 
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FigUre 1 | Continued
patient (P236_cells) by immunofluorescence analysis, reveal-
ing that not all cells stained for podoplanin (D2-40), Ki-67, 
nuclear YAP, or nuclear calretinin, while all cells expressed 
N-cadherin (Figure 1D). Changes in mesothelin, calretinin and 
podoplanin gene expression levels were also evaluated in tumor 
samples (Figure  1E). Differences observed in  vivo for selected 
mRNAs involved either in differentiation (HES1, RUNX2), 
EMT (GREM1, CTGF), senescence (PUMA, LOX, PAI1), drug 
transport (SLC22A4, ABCC1), cell cycle (CALB2 (20), CCND1, 
CDKN2A), response to oxidative stress or hypoxia (HO-1, CAIX, 
GLUT1), or MPM-associated surface proteins (PDPN, THY1, 
CD276, TNFRSF10B) were weakly (R2 = 0.2641) but significantly 
FigUre 2 | (a) Establishment in vitro of chemoresistant cell lines by exposure to gradually increasing doses of cisplatin/pemetrexed. (B) Cis/pem line established 
from patient P236A_cells is chemoresistant compared to control when challenged with pemetrexed/cisplatin. Two-way ANOVA with Bonferroni’s post hoc test, 
*p < 0.01.
FigUre 1 | (a) Tumor processing flow-chart of 235 samples, which were processed for RNA extraction, cell culture and embedding either in PFA or OCT. Samples 
showing attributes which are grayed in the chart, were not used in the live cell biobank. (B) Circos whole genome copy number variations (CNVs) view of tumor and 
primary cell culture in patients malignant pleural mesothelioma (MPM) 236 and MPM95. The quilt plot highlights the CNV and SNVs in genes that are part of MPM 
landscape (2). (c) Immunofluorescence analysis of selected markers in primary culture from patient MPM236. Scale bar 200 µm. (D) Selected genes expression 
analysis at mRNA (upper panel) and protein (lower panel) level in primary cultures derived from samples from two patients, MPM236 and MPM95. The latter one 
underwent EMT during disease progression. (e) Selected genes expression analysis at mRNA in tumor samples from patients MPM236 and MPM95. (F) Significant 
correlation between gene expression changes in tumor and primary culture from patient MPM236 at passage 3.
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correlated with differences observed in primary cultures in 
patient P236 (Figure 1F). This supports the idea of using primary 
cultures for the functional investigation of mechanisms underly-
ing tumor evolution.
Development of chemoresistance is 
accompanied by increased levels of Dna 
Damage, autophagy and senescence 
Marker β-galactosidase
Malignant pleural mesothelioma chemoresistance models have 
been described after 96  h exposure of human mesothelioma 
cell lines to high doses of pemetrexed (9) or after 15 cycles of 
combination of treatment with IC50 concentrations of cisplatin 
plus pemetrexed during 72 h followed by a recovery time in a rat 
cell line (21). We opted for a method that has been used in a study 
inducing cisplatin-resistance to ovarian cancer cell lines (12) 
(Figure  2A) to avoid acute induction of senescence-associated 
growth arrest observed using high doses of pemetrexed (9). 
Using this approach, we successfully generated a chemoresistant 
model for primary cells derived from patient P236 (Figure 2B) 
but not for primary cells derived from patient P95 (Figure S3 
in Supplementary Material). This was accompanied by a higher 
basal chemoresistance in primary cells derived from patient P95 
(IC50 2.5 vs. 1.5 µM in the primary culture from patient P236). 
Doubling time in the cultures exposed or not to cisplatin/pem-
etrexed did not differ in either of the two patients (Figure S4 in 
Supplementary Material) excluding that growth kinetics were the 
underlying mechanism of resistance.
We have previously described the occurrence of senescence in 
MPM patients treated with chemotherapy (15). Because senes-
cence is a stress response involving multiple effector mechanisms, 
including DNA damage response (22, 23), senescence-associated 
secretion phenotype (SASP) (24–28) and autophagy (29), we 
analyzed markers involved in these pathway. Consistent with 
development of chemoresistance in the cisplatin/pemetrexed 
primary culture from patient P236, we observed increased levels 
of senescence-associated β-gal activity (Figure  3A), autophagy 
markers LC3B-II (53% increase) and p62 (41% increase) and 
appearance of SASP-associated (28) GATA-4 (Figure  3B), 
FigUre 3 | (a) Senescence-associated beta-galactosidase staining in control and cis/pem adapted primary cultures from patient malignant pleural mesothelioma 
(MPM) 236 and MPM95. Scale bar 25 µm. (B) Expression of senescence-associated secretion phenotype-associated GATA-4 and autophagy activation LC3B and 
p62. (c) DNA-damage response markers γ-H2AX and p53 stabilization.
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and H2AX phosphorylation (more than sevenfold increase, 
Figure  3C). Importantly, basal levels of senescence-associated 
β-gal activity were higher in patient P95, and did not differ in 
cisplatin/pemetrexed treated cultures. In the same patient the 
expression of GATA-4 was already detected in the control primary 
culture and did not increase further in the cisplatin/pemetrexed 
culture. Increased levels of the other markers in the cisplatin/
pemetrexed compared to control culture were smaller compared 
to changes observed in patient P236. All in all, this data confirms 
that chemotherapy can induce resistance via induction of senes-
cence but also indicates that the cancer genetic background per se 
is likely responsible for senescence and resistance due to genomic 
instability.
increase in Thy1 expression in  
acquired-chemoresistance line
In order to get more insight into events occurring during the devel-
opment of chemoresistance in primary cultures from patient P236 
exposed to cisplatin/pemetrexed, we analyzed the mRNA expres-
sion of autophagy/senescence-associated IL-6 and PAI-1 (15, 30) 
and chemoresistance-development associated Thy1 (31) at three 
different time points during culture treatment (Figure 4A) and in 
the original primary cultures. Consistent with increased level of 
SASP-associated GATA4, we observed upregulation of IL-6 at the 
first two time points and in the primary culture obtained in the 
progressing tumor. PAI-1 expression followed a similar pattern. 
THY1 was decreased at the first time point then it increased, as 
also observed in the progressing tumor. We had identified Thy1 
N-glycoprotein on the cell surface of mesothelioma cells in 
MPM tumors (32), therefore, we analyzed Thy1 positive cells by 
immunofluorescence in both, control and cisplatin/pemetrexed 
adapted primary cultures and original primary cultures from the 
two specimens obtained from the tumor. We observed that Thy1 
was expressed at increased levels in primary cultures obtained 
during cisplatin/pemetrexed adaptation (Figure 4B, upper panel) 
and as well during tumor progression (Figure 4B, lower panel), 
although to a lower extent. For quantification, we performed flow 
cytometric analyses (Figure 4C) and observed a 10-fold increase 
of expression of Thy1 surface protein in cisplatin/pemetrexed 
exposed primary cells at the third time point, confirming our 
immunofluorescence data. In addition, we detected Thy1 protein 
expression by WB (data not shown) in cisplatin/pemetrexed 
adapted cells. The observation associating higher levels of Thy1 
with tumoral cell progression is consistent with Thy1 high expres-
sion levels with worst overall survival in TCGA (Figure S5 in 
Supplementary Material).
In the process of trying to better understand mechanisms 
regulating Thy1 expression, we realized that we had used prim-
ers (15) based on UCSC Genome Browser on Human Feb. 2009 
Assembly, which detect both THY1 and long non-coding RNA 
(lncRNA) RP11-334E6.12, a lncRNA in antisense orientation 
compared to THY1 and which partially overlaps with THY1 
3′UTR. We, therefore, redesigned primers recognizing individu-
ally THY1 and lncRNA RP11-334E6.12, and observed a strong 
correlation between lncRNA RP11-334E6.12 and THY1 expres-
sion (Figure 4D), which is consistent with correlated expression 
between these two gene expression reported in G.Tex (33) (Figure 
FigUre 4 | (a) Expression of senescence-associated genes IL-6 and PAI-1 and THY1/lnc RP11-334E6.12 during chemoresistance development or tumor 
progression. (B) Immunofluorescence analysis of Thy1 expression cis/pem and control lines and original primary cultures from tumor samples of malignant pleural 
mesothelioma (MPM) 236 during tumor progression. (c) Flow cytometry analysis of Thy1 expression in cis/pem vs. control line. (D) lnc RP11-334E6.12 mRNA 
expression correlates with THY1 expression in MPM tumors.
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S6 in Supplementary Material). Taken together, this data indicate 
an enrichment of THY1 positive cells during chemoresistance 
development and a possible role for lnc RP11-334E6.12 in such 
an increase.
DiscUssiOn
A national effort in UK has resulted in the establishment of 26 
primary mesothelioma cultures within the UK Mesobank (34). In 
this study, we tested the usefulness of an even larger collection of 
primary mesothelioma cell cultures, in some cases obtained from 
the same patient at different stages during disease progression. 
We aimed to carry out functional studies and provide evidence 
that changes observed in vitro and in vivo are similar.
Primary cultures in cancer research are of high value. Indeed, 
they represent primary intermediate before growth as xenograft, 
which, although providing a three-dimensional tissue environ-
ment have high-cost and low-throughput capacity. We have 
highlighted (17) the importance of primary culture and their 
growing conditions for maintenance of stem cell signaling path-
ways active in vivo (2, 35). In addition, they may represent the 
unique resource available for the 60% of MPM that do not grow 
as xenograft (36).
Although high-quality repositories such as biobanks and 
biomolecular resource infrastructures are being established (37), 
access to a large numbers of MPM biospecimens of high quality 
remains difficult. In our study, we deeply characterized samples 
from two patients, exemplifying the heterogeneity that can be 
found in real life, with one patient showing high levels of chro-
mosomal instability while in the second only minor alterations 
were observed.
In the primary culture from the patient with abundant 
chromosomal instability (P95), a basal level of chemoresistance 
associated with senescence-associated phenotype was observed. 
This is consistent with the presence of the gain of function p53 
mutation observed in this patient. Indeed p53Arg280Threo, 
although not fully oncogenic, has been shown to increase growth 
in soft agar of p53-deficient cells (38). TP53 is rarely mutated in 
MPM and in a recent high-through put study (2) mutations in 
this gene were absent in epithelioid MPM. However, datamining 
the catalog of somatic mutations in cancer (COSMIC, http://
www.sanger.ac.uk/cosmic), we found that TP53 mutations are 
described in 2/24 (8%) epithelioid mesothelioma. For this patient, 
we have already described that the side population was enriched 
in tumor initiating properties in the primary culture established 
at the time of surgery, where tumor has evolved from epithelial to 
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biphasic histotype (35), and Hedgehog signaling is maintained in 
primary cultures in serum-free conditions (17). Because we now 
show that a resistant phenotype against cisplatin/pemetrexed is 
present before chemotherapy, we infer that intrinsic properties of 
the tumor, including gain of function of TP53, deletion of NF2, 
and CDKN2A participate to the evolution of resistant cells toward 
EMT.
The tumor from the second patient (P236) was of epithelioid 
morphology, maintaining the same histotype throughout the 
course of the disease and displayed absence of gross genetic 
abnormalities. In this context, it is worth noting that in triple 
negative breast cancer, 26% of cancers lack gross genetic abnor-
malities and this is likely because they originate from an epithelial 
precursor with stemness properties (39). The second patient was 
operated again after relapsing and received chemotherapy after 
the second surgery but relapsed again.
Primary mesothelioma cultures obtained at a 4-year interval 
have already been shown to demonstrate increased drug resist-
ance but underlying mechanisms have not been examined yet 
(40). While investigating mechanisms underlying the develop-
ment of chemoresistance, we observed increased Thy1 (CD90) 
expression. Thy1 is GPI-anchored cell surface protein and in 
human the highest expression is observed in fetal thymic cells 
and subgroup of fibroblasts (41). Thy1 overexpression suppresses 
cell proliferation in ovarian and nasopharyngeal cancer (42–46), 
however, Thy1 expression in cancer stem-cells has mostly been 
associated with chemoresistance and increased tumor-initiating 
properties (47–49). Thy1 expression has been also observed 
in four tumorigenic MPM primary cell cultures grown in low 
serum conditions (50). We show here that increased Thy1 was 
associated with increased expression of lncRNA RP11-334E6.12. 
There is not much information about this lncRNA. A significant 
correlation between expression of lncRNA RP11-334E6.12 and 
developmental processes has been documented in esophageal 
cancer (51); overexpression has been documented in triple 
negative breast cancer (52). Because this lncRNA is in antisense 
orientation compared to THY1, and partially overlaps with 
THY1 3′UTR, it is tempting to speculate that it may participate 
in regulating THY1 expression. Although beyond the scope of 
this study, this hypothesis requires further investigation. In future 
studies, it would be of interest to investigate whether Thy1 expres-
sion contributes to chemoresistance and whether all MPMs are 
derived from a yet to be identified precursor cell.
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